Baxter Expanding Facilities In China To Keep Pace With Exploding Market Growth, Testing A/H1N1 Strain In U.S. For Potential Vaccine

BEIJING - The U.S.-headquartered Baxter International is reinvesting most of the $200 million in revenues it posted in China in 2008 to expand production facilities across the country, even as Baxter's American scientists begin testing a strain of the A/H1N1 virus for a potential vaccine if a pandemic is declared by the World Health Organization